TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II

Inclusion Criteria: * Understand the study procedures and voluntarily sign the informed consent form to voluntarily enroll in this study; * Age ≥ 18 years old; * Receive anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) within 14 days prior to study entry; * Anti-tumor therapy (see the subsequent 'Protocols for Reference' for details); * Patients with two consecutive platelet counts \<75×109/L more than 24 hours apart, with a screening period of 3 days. Exclusion Criteria: * Previous use of rhTPO or TPORA analogs; * Prior grade 2 or higher CTIT; * Patients undergoing clinical interventional studies; * Patients with a history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disorders, lymphoma, or myelodysplastic disorders; * Patients with underlying liver disease (e.g., cirrhosis or chronic hepatitis) and no primary or metastatic cancer in the liver will be excluded if ALT/AST \>3X ULN or total bile \>3X ULN); * Patients with the presence of primary or metastatic liver cancer will be excluded if ALT/AST \>5X ULN or total bile \>5X ULN; * Patients with a history of symptomatic venous thrombotic events (e.g., DVT or pulmonary embolism) and symptomatic arterial thrombotic events (e.g., myocardial infarction, ischemic cerebral vascular accident, or transient ischemic attack) who are unable to tolerate anticoagulant therapy will be ineligible, and patients with D-dimer greater than 10,000 g/L will also be excluded; * …